Starčević Jovana Nikolajević, Petrovič Danijel
Institute of Histology and Embryology, Medical faculty, University Ljubljana, Korytkova 2, 1000 Ljubljana, Slovenia.
Cardiovasc Hematol Agents Med Chem. 2013 Mar;11(1):3-8. doi: 10.2174/1871525711311010003.
The prognostic importance of large artery structure and function in relation to cardiovascular morbidity and mortality, together with the identification of new genetic risk factors have been two major areas of investigation in recent years. Carotid intima-media thickness (CIMT), as measured by B-mode ultrasound, is a surrogate marker for atherosclerosis and can be used to detect an accelerated disease process as well as subclinical disease. However, the genetic basis for CIMT variation is almost unknown. Cardiovascular genetics has led to numerous clinical studies generally focused on only one candidate gene and were frequently conducted in subjects with cardiovascular diseases and/or taking drugs that could affect CIMT. Pharmacogenetics is the study of the effect of a medication as it relates to single or defined sets of genes. An important goal of pharmacogenetics in cardiovascular disorders is to integrate the two (drugs plus genes) so that true personalized therapy can be delivered. In this paper, we will discuss the interaction between genes involved in lipid metabolism and statin therapy that affects intermediate phenotype (plasma lipid levels) and CIMT in patients with type 2 diabetes.
大动脉结构和功能与心血管发病率及死亡率之间的预后重要性，以及新遗传风险因素的识别，是近年来的两个主要研究领域。通过B型超声测量的颈动脉内膜中层厚度（CIMT）是动脉粥样硬化的替代标志物，可用于检测疾病进程加速以及亚临床疾病。然而，CIMT变异的遗传基础几乎未知。心血管遗传学已引发了众多临床研究，这些研究通常仅聚焦于一个候选基因，且经常在患有心血管疾病和/或正在服用可能影响CIMT的药物的受试者中进行。药物遗传学是研究药物与单个或特定基因集之间关系的学科。心血管疾病药物遗传学的一个重要目标是将两者（药物加基因）整合起来，以便能够提供真正的个性化治疗。在本文中，我们将讨论参与脂质代谢的基因与他汀类药物治疗之间的相互作用，这种相互作用会影响2型糖尿病患者的中间表型（血浆脂质水平）和CIMT。
